Quintessence Biosciences President and COO, Dr. Laura Strong, will be talking today at the Midwest Healthcare Venture Forum on new approaches to drug and device development. The panel will include Geeta Vemuri, Ph.D., M.B.A, Vice President, Head of Baxter Ventures and will be moderated by Ed Silverman, Special Writer, Pharmalot blog, The Wall Street Journal.
About Quintessence Biosciences Quintessence Biosciences, Inc. is a private company developing novel anti-cancer compounds based on our patented EVade™ Ribonuclease technology. The drug is differentiated, targeting the RNA in cancer cells. Dose escalation of our most advanced lead candidate, QBI-139, in a Phase I trial has recently been completed. The safety profile of the drug is distinct from chemotherapy. Based on encouraging signs of efficacy, partners are being sought for expansion cohorts to evaluate efficacy of QBI-139 in defined patient populations. The drug had a strong therapeutic window against a variety of in vivo xenograft models including: colon, non-small cell lung, ovarian, pancreatic and prostate cancer.
About the Midwest Healthcare Venture Forum Held March 10-11 in Chicago, MidAmerica Healthcare Venture Forum is the premier healthcare investing conference. Over 300 innovative thought-leaders, prominent industry players, venture capitalists and angel investors will gather in Chicago in March, to discuss latest trends in reimbursement, a status update on healthcare accelerators, best approaches to commercialization and new business models in healthcare and beyond.
15 June 2012 - Quintessence Biosciences Meeting with Partners at 2012 BIO International Convention
31 May 2012 - Quintessence Biosciences Presents on Phase I trial of Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Annual Meeting
19 April 2012 - Quintessence Biosciences Selected for Buzz of BIO at 2012 BIO International Convention
12 April 2012 - Quintessence Biosciences Announces Election of Walter Dewey to Board of Directors
30 March 2012 - Quintessence Biosciences Presents Results for Combination Studies of Clinical Stage Ribonuclease QBI-139 at AACR Meeting
15 January 2010 - Quintessence Biosciences to Present at Keystone Symposia's RNA Silencing Conference